Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TYRA
stocks logo

TYRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.570
+32.56%
--
--
-0.564
+20%
--
--
-0.556
+18.3%
Estimates Revision
Stock Price
Go Up
up Image
+74.78%
In Past 3 Month
Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is 32.40 USD with a low forecast of 28.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is 32.40 USD with a low forecast of 28.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.110
sliders
Low
28.00
Averages
32.40
High
36.00
Current: 22.110
sliders
Low
28.00
Averages
32.40
High
36.00
Goldman Sachs
initiated
2025-12-04
New
Reason
Goldman Sachs
Price Target
2025-12-04
New
initiated
Reason
Goldman Sachs initiated coverage of Tyra Biosciences with an Early-Stage Biotech rating. Tyra is a clinical stage biotechnology company using its proprietary drug-discovery platform to develop precision medicines to address significant unmet need, the analyst tells investors in a research note.
Oppenheimer
Matthew Biegler
Outperform
maintain
$30 -> $36
2025-09-10
Reason
Oppenheimer
Matthew Biegler
Price Target
$30 -> $36
2025-09-10
maintain
Outperform
Reason
Oppenheimer analyst Matthew Biegler raised the firm's price target on Tyra Biosciences to $36 from $30 and keeps an Outperform rating on the shares after hosting the company for meetings in Boston on Monday. In each meeting, management made the case for why dabogratinib's combined market opportunity exceeds $10B. That's nearly Regeneron-esque revenues. Despite that, investors still complain that all the major catalysts aren't until 2026. NULLtheless, the firm tells investors, "don't expect to find shares at this price - with a sub-$500M enterprise value - next year."
Raymond James
analyst
Strong Buy
initiated
$35
2025-09-02
Reason
Raymond James
analyst
Price Target
$35
2025-09-02
initiated
Strong Buy
Reason
Raymond James initiated coverage of Tyra Biosciences with a Strong Buy rating and $35 price target. Tyra's unique SNAP development platform, as validated with the first discovery candidate, TYRA-300, is "potentially best-in-class," says the analyst, who sees "multi-billion-dollar revenue potential" in the indications being investigated.
Piper Sandler
Allison Bratzel
Overweight
initiated
$33
2025-05-21
Reason
Piper Sandler
Allison Bratzel
Price Target
$33
2025-05-21
initiated
Overweight
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-03-31
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$30
2025-03-31
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$30
2025-02-18
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$30
2025-02-18
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tyra Biosciences Inc (TYRA.O) is -9.96, compared to its 5-year average forward P/E of -8.68. For a more detailed relative valuation and DCF analysis to assess Tyra Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.68
Current PE
-9.96
Overvalued PE
-4.19
Undervalued PE
-13.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.39
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.52
Undervalued EV/EBITDA
-19.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1354.65% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1354.65% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TYRA News & Events

Events Timeline

(ET)
2025-12-01
08:20:00
Tyra Biosciences Appoints New Executives to Advance Drug Development
select
2025-11-05 (ET)
2025-11-05
16:18:23
Tyra Biosciences announces Q3 earnings per share of 50 cents, slightly below consensus estimate of 51 cents.
select
2025-08-21 (ET)
2025-08-21
08:02:12
Tyra Biosciences announces first pediatric patient treated in BEACH301 trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01PRnewswire
Tyra Biosciences Appoints New Executives to Advance FGFR Drug Development
  • Executive Appointments: Tyra Biosciences has appointed Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer, who will be pivotal in advancing oral dabogratinib through global Phase 2 trials for skeletal dysplasia and urologic cancers.
  • Extensive Experience: Ashar brings over 25 years of pharmaceutical and biotechnology experience, having served as Chief Commercial Officer at SpringWorks Therapeutics where he successfully launched two rare oncology products, while Faulds has over 20 years in regulatory strategy, most recently as SVP of Global Regulatory Sciences at Blueprint Medicines.
  • Clinical Development Plans: Oral dabogratinib, TYRA's lead precision medicine candidate, is currently undergoing global Phase 2 clinical trials targeting pediatric achondroplasia and intermediate-risk non-muscle invasive bladder cancer, with the FDA granting Orphan Drug and Rare Pediatric Disease designations.
  • Strategic Implications: The executive appointments and clinical development initiatives signify Tyra's strategic positioning in FGFR biology, aiming to enhance patient quality of life through precision medicines that address significant unmet medical needs.
[object Object]
Preview
5.0
11-18Yahoo Finance
Insider at Tyra Biosciences Sells Shares Valued at $2,108,067, Recent SEC Filing Reveals

  • Sale of Shares: Daniel Bensen, the Chief Operating Officer of Tyra Bioscience, sold 131,411 shares on November 13, 2025.

  • Impact on Portfolio: The sale may have implications for his personal portfolio and the company's stock performance.

[object Object]
Preview
1.0
11-13PRnewswire
Tyra Biosciences Announces Participation at Upcoming Investor Events

  • Investor Events Participation: Tyra Biosciences will participate in the Jefferies London Healthcare Conference on November 19, 2025, and the 37th Annual Piper Healthcare Conference from December 2-4, 2025, with formats including hybrid presentations and one-on-one meetings.

  • Company Overview: Tyra Biosciences is a clinical-stage biotechnology company focused on precision medicines targeting FGFR biology, with a pipeline that includes potential first-in-class therapies for various cancers and genetic conditions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tyra Biosciences Inc (TYRA) stock price today?

The current price of TYRA is 22.11 USD — it has increased 1.89 % in the last trading day.

arrow icon

What is Tyra Biosciences Inc (TYRA)'s business?

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

arrow icon

What is the price predicton of TYRA Stock?

Wall Street analysts forecast TYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TYRA is 32.40 USD with a low forecast of 28.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tyra Biosciences Inc (TYRA)'s revenue for the last quarter?

Tyra Biosciences Inc revenue for the last quarter amounts to -32.94M USD, increased 15.17 % YoY.

arrow icon

What is Tyra Biosciences Inc (TYRA)'s earnings per share (EPS) for the last quarter?

Tyra Biosciences Inc. EPS for the last quarter amounts to -22419000.00 USD, increased 24.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tyra Biosciences Inc (TYRA)'s fundamentals?

The market is revising No Change the revenue expectations for TYRA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 74.78%.
arrow icon

How many employees does Tyra Biosciences Inc (TYRA). have?

Tyra Biosciences Inc (TYRA) has 60 emplpoyees as of December 05 2025.

arrow icon

What is Tyra Biosciences Inc (TYRA) market cap?

Today TYRA has the market capitalization of 1.18B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free